Elanco Animal Health (ELAN) Tops Q2 EPS by 7c; offers guidance

Elanco Animal Health (NYSE: ELAN) reported Q2 EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.31 billion.

GUIDANCE:

Elanco Animal Health sees Q3 2026 EPS of $0.19-$0.22, versus the consensus of $0.19. Elanco Animal Health sees Q3 2026 revenue of $1.195-1.22 billion, versus the consensus of $1.19 billion.

Elanco Animal Health sees FY2026 EPS of $1.10-$1.16, versus the consensus of $1.07. Elanco Animal Health sees FY2026 revenue of $5.09-5.14 billion, versus the consensus of $5.054 billion.

For earnings history and earnings-related data on Elanco Animal Health (ELAN) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Stem notified of NYSE noncompliance over market cap and equity
• RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)